- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03977896
Feasibility of 11C-MET PET/MRI Imaging in Pediatric Brain Fossa Tumors (TI-TFCE)
Pilot Study to Evaluate the Feasibility of Hybrid Brain Imaging 11C-MET PET/MRI of Posterior Brain Fossa Tumors in Children
Brain tumors are the most common solid tumors in children and are the second most common cause of cancer-related death among this population. Posterior brain fossa tumors represent about 50% of children brain tumors.
Recently, knowledge in molecular biology has permitted to identify different tumors subgroups of very different prognosis. Today, surgery removal of the tumor is the mandatory. Neuro-oncological treatment differs depending on the histological and molecular subgroup. With classical Magnetic Resonance Imaging (cMRI), distinction between different types of posterior fossa tumors remains difficult.
Positron Emission Tomography combined with MRI (PET/MRI) has proven its benefits for the management of brain tumors. The direct spatiotemporal correlation makes possible the assessment of metabolic, anatomical and functional information. PET/MRI would provide precisions on the pre-therapeutic characterization of tumors, which could permit to modify the patients' care.
L- [methyl-11C] methionine (11C-MET) is currently the gold-standard tracer used in neuro-oncology, but few data exists in children. 11C-MET PET/MRI assessment seems promising, but has not been studied enough. To the best of our knowledge, there is no specific study on primary brain tumors of the posterior fossa in children using 11C-MET PET/MRI.
The primary objectives of this first pilot study is to evaluate the practical feasibility of 11C-MET PET/MRI imaging (machine accessibility and imaging interpretability) before surgery in a population of children older than 5 years old with posterior fossa tumors.
The secondary objectives aim to describe :
- the PET/MRI parameters of the different tumors studied,
- and the patient's participation acceptation.
This feasibility study will allow us to standardize the PET/MRI measurements; this could allow us to discriminate, in a larger study, the different tumor subgroups before surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bron, France
- Hospices Civils de Lyon - Groupement Hospitalier Est - Hôpital Femme Mère Enfant - Service de Neurochirurgie Pédiatrique
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients ≥ 5 years old and < 18 years old at enrollment,
- with primary posterior brain fossa tumor, metastatic or not,
- hospitalized in the Department of Pediatric Neurosurgery of Femme-Mère-Enfant Hospital, and for whom a surgery is scheduled,
- covered by national health insurance,
- patient's parents or legal guardians who have provided written informed consent prior to participation in the study.
Exclusion Criteria:
- Patients with contraindication for MRI (claustrophobia, carrying metallic object)
- Patients with contraindication for Gadolinium injection (including pregnancy and breastfeeding)
- patient with recurring posterior brain fossa tumor
- patient with brain stem infiltrative tumor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 11C-MET PET/MRI
|
Except PET/MRI imaging, all the examinations will be done according to the patient's usual care. PET/MRI imaging will be realized within max 7 days after children enrollment, and the surgery (usual care) will be performed within max 4 days after PET/MRI imaging. PET/MRI imaging will include the following sequences: T1axial, Diffusion, Magnetic susceptibility post-Gadolinium injection, 3DT1 pre and post-Gadolinium injection, and Arterial Spin Labelling Imaging (ASL). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of patients who performed the PET/MRI
Time Frame: 7 days
|
7 days
|
|
number of patients called in for PET/MRI who have not realized the PET/MRI
Time Frame: 7 days
|
7 days
|
|
number of patients with good quality of the imaging
Time Frame: 7 days
|
The interpretability of the imaging will be evaluated by a Review Committee (two pairs composed each by a radiologist (for MRI imaging) and a nuclear physician (for PET imaging)).
The imaging will be classified under good or bad quality
|
7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pierre-Aurélien BEURIAT, MD, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL18_0867
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Posterior Brain Fossa Tumors in Children
-
Baxter Healthcare CorporationCompletedDura Defects | Pathological Processes in the Posterior FossaUnited States, Canada
-
Istanbul UniversityCompleted
-
Children's National Research InstituteWithdrawnArnold-Chiari Malformation | Posterior Fossa TumorsUnited States
-
Medical University InnsbruckRecruitingIntracranial Pressure Increase | Posterior Fossa Lesion | Posterior Fossa HemorrhageAustria
-
Great Ormond Street Hospital for Children NHS Foundation...CompletedCerebellar Mutism | Posterior Fossa SyndromeUnited Kingdom
-
Kasr El Aini HospitalCompleted
-
University Hospital, Strasbourg, FranceGustave Roussy, Cancer Campus, Grand ParisCompletedRefractory Solid Tumors in ChildrenFrance
-
Children's Cancer Hospital Egypt 57357CompletedMedulloblastoma, Childhood | Posterior Fossa TumorEgypt
-
Kasr El Aini HospitalCompletedPosterior Fossa TumorEgypt
-
Tang-Du HospitalRecruitingPosterior Fossa HemorrhageChina
Clinical Trials on 11C-MET PET/MRI
-
Massachusetts General HospitalRecruitingDiabetes | Aortic Valve Stenosis | Heart Failure With Normal Ejection Fraction | Left Ventricular HypertrophyUnited States
-
University of PennsylvaniaRecruiting
-
Turku University HospitalCompleted
-
IRCCS San RaffaeleRecruiting
-
Massachusetts General HospitalCompleted
-
Hospices Civils de LyonCompleted
-
University of British ColumbiaBritish Columbia Cancer AgencyUnknownPrimary HyperparathyroidismCanada
-
University of MichiganTerminated
-
Yale UniversityNational Institute of Mental Health (NIMH); National Institutes of Health (NIH)RecruitingHealthy | HIV Dementia | HIV Associated Neurocognitive Disorder | HIV EncephalitisUnited States